Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) antibodies pairs and antigen for animal health (animal Equine/Horse infectious disease Equine/Horse theileriosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Equine/Horse disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P144-Tg001-Ag01	Recombinant Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) protein	$3090.00
GMP-VT-P144-Tg001-Ab01	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P144-Tg001-Ab02	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P144-Tg001-Ab03	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) human monoclonal antibody (mAb)	$3090.00
GMP-VT-P144-Tg001-Ab04	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P144-Tg001-Ag01
Product Name	Recombinant Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) protein
Pathogen	Theileria equi
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Theileria equi level test of animal Equine/Horse infectious disease with Equine/Horse theileriosis.
Tag	His
Product description	Recombinant Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P144-Tg001-Ab01,GMP-VT-P144-Tg001-Ab02
Pathogen	Theileria equi
Product Name	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Theileria equi antibodies in Theileria equi level test of animal Equine/Horse infectious disease with Equine/Horse theileriosis.
Product description	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Theileria equi antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P144-Tg001-Ab03,GMP-VT-P144-Tg001-Ab04
Pathogen	Theileria equi
Product Name	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Theileria equi antibodies in Theileria equi level test of animal Equine/Horse infectious disease with Equine/Horse theileriosis.
Product description	Anti-Theileria equi Equine/Horse merozoite surface antigen-1 (EMA1) mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Theileria equi is a protozoan parasite that infects horses. The organism belongs to the phylum Apicomplexa, which encompasses a diverse group of parasitic eukaryotic organisms that infect a wide range of hosts. The apicomplexans are characterized by the presence of complex organelles called apical complexes that play essential roles in the invasion and replication of the organisms within their host cells.

Equine piroplasmosis is a tick-borne disease caused by Theileria equi. The disease is endemic in many regions of the world, including parts of Africa, Asia, the Middle East, South America, and some parts of Europe. The pathogen is transmitted to horses through the bite of infected ticks, primarily those belonging to the genera Hyalomma and Rhipicephalus.

Upon entering the host's bloodstream, the tick-borne parasite infects and replicates within red blood cells, leading to anemia and other associated clinical signs. Some of the symptoms of equine piroplasmosis include fever, depression, anorexia, weight loss, jaundice, and anemia. In severe cases, the disease can lead to death.

The pathological mechanisms underlying equine piroplasmosis are complex and multifactorial. Theileria equi invades host red blood cells, where it undergoes several developmental stages before being released into the bloodstream to infect other cells. The destruction of infected red blood cells leads to the clinical manifestations of the disease, such as anemia.

The main virulence factors of Theileria equi are not yet clearly defined. However, recent studies suggest that the pathogen manipulates host immune responses to evade detection and clearance by the host's immune system. Specifically, the pathogen modulates cytokine production and T-cell responses to establish a persistent infection in the host.

Diagnosis of equine piroplasmosis is challenging, primarily due to the nonspecific and variable clinical signs of the disease. However, several diagnostic methods can aid in the identification of the pathogen. Serological tests are frequently used to detect specific antibodies against Theileria equi in infected animals. The ELISA and IFAT are two common serological tests that provide reliable and sensitive outcomes.

More recently, nucleic acid-based tests have been developed for the rapid detection of Theileria equi in infected horses. PCR-based techniques targeting the 18S ribosomal RNA gene and the merozoite surface antigen gene provide reliable and sensitive outcomes in detecting the pathogen's genetic material in blood samples. Further research into the pathogen's molecular biology and virulence mechanisms can help identify new diagnostic targets and therapeutic strategies for equine piroplasmosis.

In conclusion, Theileria equi is a tick-borne protozoan parasite that causes equine piroplasmosis. The pathogen invades host red blood cells, leading to anemia and other associated clinical signs. Diagnosis of the disease remains challenging, but several diagnostic methods, including serological and nucleic acid-based tests, can aid in its identification. Continued research into the pathogen's molecular biology and virulence mechanisms is necessary to develop new diagnostic and treatment strategies for this disease.

About GDU